Iqvia Holdings Inc (NYSE:IQV) major shareholder Cpp Investment Board Private H sold 7,497,807 shares of the firm’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $102.00, for a total transaction of $764,776,314.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Cpp Investment Board Private H also recently made the following trade(s):
- On Tuesday, September 19th, Cpp Investment Board Private H sold 6,748,026 shares of Iqvia stock. The stock was sold at an average price of $94.87, for a total transaction of $640,185,226.62.
Iqvia Holdings Inc (NYSE:IQV) opened at $101.01 on Thursday. The company has a current ratio of 1.22, a quick ratio of 1.22 and a debt-to-equity ratio of 1.29. The firm has a market cap of $21,316.11, a price-to-earnings ratio of 23.12, a P/E/G ratio of 1.66 and a beta of 0.61. Iqvia Holdings Inc has a 1-year low of $74.73 and a 1-year high of $110.67.
Iqvia (NYSE:IQV) last posted its earnings results on Thursday, October 26th. The medical research company reported $1.19 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.14 by $0.05. Iqvia had a net margin of 0.58% and a return on equity of 12.60%. The business had revenue of $2.02 billion for the quarter, compared to analyst estimates of $2.01 billion. During the same quarter in the previous year, the business posted $1.00 EPS. The business’s quarterly revenue was up 77.6% on a year-over-year basis. research analysts forecast that Iqvia Holdings Inc will post 4.62 earnings per share for the current fiscal year.
IQV has been the subject of a number of recent research reports. KeyCorp reissued a “sector weight” rating and set a $100.00 price objective on shares of Iqvia in a research note on Friday, November 10th. Zacks Investment Research raised shares of Iqvia from a “hold” rating to a “buy” rating and set a $107.00 target price for the company in a research note on Wednesday, October 11th. Credit Suisse Group reaffirmed an “outperform” rating and issued a $110.00 target price (up from $98.00) on shares of Iqvia in a research note on Monday, October 16th. BidaskClub raised shares of Iqvia from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 19th. Finally, Mizuho cut shares of Iqvia from a “buy” rating to a “neutral” rating and set a $90.00 target price for the company. in a research note on Thursday, November 9th. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Iqvia currently has an average rating of “Buy” and an average price target of $105.23.
WARNING: This piece was posted by Stock Observer and is the property of of Stock Observer. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.thestockobserver.com/2017/12/07/iqvia-holdings-inc-iqv-major-shareholder-sells-764776314-00-in-stock.html.
Iqvia Company Profile
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Iqvia Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.